| scholarly article | Q13442814 |
| P50 | author | Razelle Kurzrock | Q56614941 |
| Apostolia Maria Tsimberidou | Q56761627 | ||
| Aung Naing | Q71793401 | ||
| Filip Janku | Q73569186 | ||
| P2093 | author name string | Kenneth Aldape | |
| Gerald S Falchook | |||
| David S Hong | |||
| Siqing Fu | |||
| Yang Ye | |||
| Jennifer J Wheler | |||
| Sarina Piha-Paul | |||
| Sijin Wen | |||
| Donald Berry | |||
| P2860 | cites work | Comprehensive molecular portraits of human breast tumours | Q24630844 |
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| Systematic identification of genomic markers of drug sensitivity in cancer cells | Q29547695 | ||
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 | ||
| The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups | Q29614700 | ||
| The clonal and mutational evolution spectrum of primary triple-negative breast cancers | Q29619914 | ||
| The BATTLE trial: personalizing therapy for lung cancer | Q34275011 | ||
| Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors | Q35535953 | ||
| Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative | Q35680026 | ||
| PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations | Q35808438 | ||
| Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival | Q36070080 | ||
| Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers | Q50539670 | ||
| Analysis of survival by tumor response. | Q52874285 | ||
| Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables | Q81798459 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | personalized medicine | Q2072214 |
| P304 | page(s) | 4827-4836 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses | |
| P478 | volume | 20 |
| Q59134800 | A Pilot Prospective Study of Refractory Solid Tumor Patients for NGS-Based Targeted Anticancer Therapy |
| Q96127147 | A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study |
| Q38961012 | A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials |
| Q34781122 | A framework for genomic biomarker actionability and its use in clinical decision making |
| Q88887124 | A nonparametric Bayesian basket trial design |
| Q35810461 | Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA |
| Q50095063 | Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology |
| Q34295621 | Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer |
| Q38694488 | Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer |
| Q45943221 | Breast cancer: The translation of big genomic data to cancer precision medicine. |
| Q35749677 | Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes. |
| Q53577839 | Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. |
| Q36192000 | Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials |
| Q33873653 | Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors. |
| Q90813081 | Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing |
| Q48472939 | Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients |
| Q40193932 | Comparative molecular profiling of HPV-induced squamous cell carcinomas. |
| Q99408621 | Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program |
| Q33888813 | Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer |
| Q40218092 | Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options |
| Q38822358 | Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma |
| Q53117937 | Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials. |
| Q36317783 | Data resources for the identification and interpretation of actionable mutations by clinicians. |
| Q21131727 | Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy |
| Q89181553 | Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC |
| Q90452339 | Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies |
| Q38784010 | Equal access to innovative therapies and precision cancer care |
| Q49897564 | Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits. |
| Q53741649 | Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. |
| Q52354170 | From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards. |
| Q48013156 | Functional precision cancer medicine-moving beyond pure genomics |
| Q64982130 | Genetic characterisation of molecular targets in carcinoma of unknown primary. |
| Q58801101 | Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications |
| Q47156715 | Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study |
| Q36534696 | Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials |
| Q36064946 | Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center |
| Q89765536 | Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study |
| Q33677392 | Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center |
| Q92684916 | Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI |
| Q92332067 | Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine |
| Q37631514 | Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? |
| Q96954974 | Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board |
| Q36843773 | Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. |
| Q37337359 | Molecular profiling of head and neck squamous cell carcinoma |
| Q38581287 | Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial |
| Q31043365 | Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data. |
| Q58582603 | Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients |
| Q37225334 | Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies |
| Q88917856 | Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design |
| Q92827446 | Neoantigen vaccine: an emerging tumor immunotherapy |
| Q47129835 | Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? |
| Q58586682 | Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing |
| Q88952320 | OncoKB: A Precision Oncology Knowledge Base |
| Q56395253 | Overview of precision oncology trials: challenges and opportunities |
| Q88559910 | Pathogenetic Analysis of Sinonasal Teratocarcinosarcomas Reveal Actionable β-catenin Overexpression and a β-catenin Mutation |
| Q89456670 | Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative |
| Q47109191 | Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. |
| Q90017809 | Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board |
| Q36328010 | Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer |
| Q33429608 | Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer |
| Q36288987 | Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials |
| Q47406496 | Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy |
| Q39124225 | Precision medicine needs randomized clinical trials |
| Q47581792 | Precision medicine strategies in oncology: mixed approaches to matched therapies |
| Q47692675 | Precision oncology using a clinician-directed, tailored approach to molecular profiling. |
| Q92353188 | Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer |
| Q89139059 | Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials |
| Q64119002 | Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study |
| Q55380623 | Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie. |
| Q64235743 | Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology |
| Q49719290 | Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome |
| Q99551838 | Sequencing for an interdisciplinary molecular tumor board in patients with advanced breast cancer: experiences from a case series |
| Q38810603 | Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma |
| Q35589492 | Targeted therapies for advanced Ewing sarcoma family of tumors |
| Q37204270 | Targeted therapy in cancer |
| Q42699046 | The SHIVA01 trial: what have we learned? |
| Q38724312 | The State of the Art in Colorectal Cancer Molecular Biomarker Testing |
| Q28072144 | The possibility of clinical sequencing in the management of cancer |
| Q50345037 | The rise of genomic profiling in ovarian cancer |
| Q38454659 | Toward precision medicine in glioblastoma: the promise and the challenges |
| Q55432258 | Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy. |
| Q64117310 | Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies |
| Q26776394 | Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials |
| Q39888234 | Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers |
| Q55339672 | Value-based genomics. |
| Q36845431 | rCGH: a comprehensive array-based genomic profile platform for precision medicine |
Search more.